DK1267885T3 - Formulering til svangerskabsforebyggelse hos mænd, hvilken formulering indeholder norethisteron og testoteronundecanoat - Google Patents

Formulering til svangerskabsforebyggelse hos mænd, hvilken formulering indeholder norethisteron og testoteronundecanoat

Info

Publication number
DK1267885T3
DK1267885T3 DK01902590T DK01902590T DK1267885T3 DK 1267885 T3 DK1267885 T3 DK 1267885T3 DK 01902590 T DK01902590 T DK 01902590T DK 01902590 T DK01902590 T DK 01902590T DK 1267885 T3 DK1267885 T3 DK 1267885T3
Authority
DK
Denmark
Prior art keywords
norethisterone
formulation
undecanoate
contraception
testoterone
Prior art date
Application number
DK01902590T
Other languages
Danish (da)
English (en)
Inventor
Eberhard Nieschlag
Axel Kamischke
Michael Oettel
Alexander Ruebig
Ekkerhard Schillinger
Ursula-Friederike Habenicht
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Application granted granted Critical
Publication of DK1267885T3 publication Critical patent/DK1267885T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK01902590T 2000-02-15 2001-02-15 Formulering til svangerskabsforebyggelse hos mænd, hvilken formulering indeholder norethisteron og testoteronundecanoat DK1267885T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50372900A 2000-02-15 2000-02-15
EP00200493 2000-02-15
PCT/IB2001/000188 WO2001060376A1 (en) 2000-02-15 2001-02-15 Male contraceptive formulation comprising norethisterone

Publications (1)

Publication Number Publication Date
DK1267885T3 true DK1267885T3 (da) 2007-07-09

Family

ID=26071832

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01902590T DK1267885T3 (da) 2000-02-15 2001-02-15 Formulering til svangerskabsforebyggelse hos mænd, hvilken formulering indeholder norethisteron og testoteronundecanoat

Country Status (26)

Country Link
EP (2) EP1267885B8 (enExample)
JP (1) JP2003522795A (enExample)
KR (1) KR20020086905A (enExample)
CN (1) CN1423560A (enExample)
AT (2) ATE355844T1 (enExample)
AU (1) AU2001230447A1 (enExample)
BG (1) BG107066A (enExample)
BR (1) BR0108411A (enExample)
CA (1) CA2398063A1 (enExample)
CY (1) CY1106639T1 (enExample)
CZ (1) CZ20022691A3 (enExample)
DE (2) DE60127103T2 (enExample)
DK (1) DK1267885T3 (enExample)
EE (1) EE200200454A (enExample)
ES (1) ES2282230T3 (enExample)
HK (1) HK1049442B (enExample)
HU (1) HUP0300128A3 (enExample)
IL (1) IL151219A0 (enExample)
MX (1) MXPA02007675A (enExample)
NO (1) NO20023607L (enExample)
PL (1) PL357185A1 (enExample)
PT (1) PT1267885E (enExample)
RU (1) RU2002124602A (enExample)
SI (1) SI1267885T1 (enExample)
SK (1) SK11602002A3 (enExample)
WO (1) WO2001060376A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10234525A1 (de) * 2002-07-25 2004-02-05 Schering Ag Zusammensetzung, enthaltend ein androgenes 11ß-Halogensteroid und ein Gestagen sowie männliches Kontrazeptivum auf Basis dieser Zusammensetzung
TW200404552A (en) * 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
NZ549529A (en) 2002-07-24 2008-04-30 Schering Aktiengellschaft Microbiological processes for the production of 7alpha-substituted 11alpha-hydroxy steroids
WO2004011008A1 (de) * 2002-07-25 2004-02-05 Schering Aktiengesellschaft ZUSAMMENSETZUNG, ENTHALTEND EIN ANDROGENES 11β-HALOGENSTEROID UND EIN GESTAGEN SOWIE MÄNNLICHES KONTRAZEPTIVUM AUF BASIS DIESER ZUSAMMENSETZUNG
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
CN101352443B (zh) * 2007-07-23 2011-01-12 中国科学院动物研究所 哺乳动物雄性不育剂
KR102496504B1 (ko) 2018-03-23 2023-02-06 라보라뚜아르 마조르 남성 피임을 위한 비호르몬 조성물 및 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714420A1 (de) * 1976-06-01 1977-12-08 Int Pregnancy Advisory Service Antikonzeptionsmittel zur verabreichung an mann und frau in einer gemeinsamen verabreichungspackung
US4210644A (en) 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
US5035891A (en) 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
CN1102095A (zh) * 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
DE19650352A1 (de) * 1996-12-04 1998-07-30 Jenapharm Gmbh Oral wirksames Kombinationspräparat zur Kontrazeption für den Mann

Also Published As

Publication number Publication date
CA2398063A1 (en) 2001-08-23
NO20023607L (no) 2002-10-15
JP2003522795A (ja) 2003-07-29
HK1049442B (en) 2007-06-15
EP1666044A1 (en) 2006-06-07
CZ20022691A3 (cs) 2003-01-15
AU2001230447A1 (en) 2001-08-27
MXPA02007675A (es) 2004-02-26
ATE474580T1 (de) 2010-08-15
EP1267885B8 (en) 2007-06-20
SI1267885T1 (sl) 2007-08-31
SK11602002A3 (sk) 2003-03-04
HUP0300128A3 (en) 2004-03-29
HK1049442A1 (en) 2003-05-16
WO2001060376A1 (en) 2001-08-23
ATE355844T1 (de) 2007-03-15
DE60127103T2 (de) 2007-11-22
EE200200454A (et) 2003-12-15
DE60127103D1 (de) 2007-04-19
PT1267885E (pt) 2007-05-31
DE60142647D1 (de) 2010-09-02
EP1267885B1 (en) 2007-03-07
BG107066A (en) 2003-05-30
PL357185A1 (en) 2004-07-26
CN1423560A (zh) 2003-06-11
IL151219A0 (en) 2003-04-10
EP1666044B1 (en) 2010-07-21
KR20020086905A (ko) 2002-11-20
BR0108411A (pt) 2003-03-11
CY1106639T1 (el) 2012-01-25
NO20023607D0 (no) 2002-07-30
HUP0300128A2 (en) 2003-05-28
ES2282230T3 (es) 2007-10-16
EP1267885A1 (en) 2003-01-02
RU2002124602A (ru) 2004-03-10

Similar Documents

Publication Publication Date Title
CY1106639T1 (el) Τυποποιηση αντισυλληπτικου για ανδρες που περιλαμβανει νορεθιστερονη
NO20032805D0 (no) Preparater av östrogensyklodekstrinkomplekser
HK1056181A1 (zh) 作為抗炎劑的17β-硫代羧酸酯17α-芳基羰氧基氧雄甾烷衍生物
HUP9900301A2 (hu) Hormontapasz
AR073972A2 (es) Composiciones farmaceuticas para el tratamiento de carencias estrogenicas en la menopausia y para la prevencion de la osteoporosis en mujeres menopausicas
AU2001273125A1 (en) Combinations of bisphosphonates, estrogenic agents and optionally estrogens
DE59510887D1 (de) Feste arzneiformen, enthaltend clathrate vom steroidalen sexualhormon ethinylestradiol
ATE225800T1 (de) Nichtestrogene derivate des estradiols mit antioxidativer aktivität
WO2002019982A3 (en) Cosmetic composition and method for reducing or preventing wrinkling
IL153540A0 (en) THE USE OF 7beta-HYDROXY-STEROID DERIVATIVES FOR THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS
MXPA05010871A (es) Metodos para administrar estrogenos y progestinas.
ZA200201250B (en) Non-aromatic estrogenic steroids with a hydrocarbon substituent in position 11.
AR027526A1 (es) Formulacion anticonceptiva masculina que comprende noretisterona
PE20010579A1 (es) Mesoprogestinas (modulares de receptores de progesterona) como componentes de anticonceptivos femeninos
JP2003522795A5 (enExample)
JP2005532336A (ja) 新規なエトノゲストレルエステルの使用
WO2003032924A3 (en) Novel tibolone formulations
PL360669A1 (en) 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds
GB1060632A (en) Steroid compositions
AR034194A1 (es) Un compuesto esteroide, su uso, una composicion farmaceutica que lo comprende y un kit para la anticoncepcion masculina
ECSP034605A (es) Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas